

IN THE CLAIMS

Please amend the claims as follows:

Claims 1-38 (Withdrawn)

Claim 39 (Currently Amended): A method of detecting ~~Type 1 diabetes~~
autoantibodies directed against ZnT-8 in a subject comprising:
contacting serum from a subject with a ZnT-8 polypeptide comprising SEQ ID NO: 2
or an antigenic fragment thereof selected from the group consisting of SEQ ID NOS: 7, 8, 9
and 10; and
detecting complex formation between autoantibodies in the serum and the ZnT-8
polypeptide or an antigenic fragment of ZnT-8;
wherein complex formation is indicative of the presence of autoantibodies directed
against ZnT-8 in the subject's serum ~~and autoantibodies correlate with an increased risk of~~
~~Type 1 diabetes.~~

Claim 40 (Currently Amended): The method of claim 39, comprising contacting the
serum with a ZnT-8 polypeptide comprising SEQ ID NO: 2.

Claims 41-45 (Cancelled)

Claim 46 (Previously Presented): The method of claim 39, wherein the detecting
comprises an immunoenzymatic detecting.

Claim 47 (Previously Presented): The method of claim 39, wherein the detecting comprises an immunochemical detecting.

Claim 48 (Previously Presented): The method of claim 39, wherein the detecting comprises an immunochemical detecting and an immunoenzymatic detecting.

Claim 49 (Currently Amended): The method of claim 39, wherein complex formation occurs on a chip comprising said ZnT-8 polypeptide or an antigenic fragment thereof.

Claim 50 (Currently Amended): The method of claim 49, wherein complex formation occurs on a chip comprising [[a]] a ZnT-8 polypeptide comprising of SEQ ID NO: 2.

Claim 51 (Currently Amended): The method of claim 49, wherein complex formation occurs on a chip comprising an antigenic fragment of the a ZnT-8 polypeptide of SEQ ID NO: 2 selected from the group consisting of SEQ ID NOS: 7, 8, 9 and 10.

Claims 52-55 (Cancelled)